The largest health insurer advocacy organization urged federal regulators to reject hospital-sought rules to limit the ability of Medicare Advantage [...] …
Articles by : Rich Daly, Editor in Chief
California health centers that participate in the 340B program recently appealed a federal district judge’s dismissal of a suit to reverse [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An independent cancer care practice is suing a Philadelphia health system in federal court over a range of alleged anti-competitive [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two drugmakers owe repayment to 340B covered entities, according to final audits posted this week by federal officials. American Health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Jazz Pharmaceuticals this week became the 25th drug manufacturer to impose conditions on 340B pricing involving delivery to contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The California Senate recently cleared a bill to bar pharmacy benefit manager (PBM) alleged discrimination against 340B covered entities and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Republican House leaders were expected introduce—as soon as Sept. 8—and quickly advance a combined package of healthcare bills that includes [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eligible covered entities in Florida may enroll in the 340B program immediately rather than having to wait for the next [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
While federal regulators recently extended the comment period on a proposed lump sum repayment plan for hospitals Illegally underpaid for [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Draft legislation that would exclude some generics from 340B and focus on penny pricing recently drew criticism from provider advocates. [...] …